J. Widén

DEBRISOQUINE HYDROXYLATION POLYMORPHISM AND PERSONALITY

C. Alm, L. Bertilsson, D. Schalling, 1989, The Lancet.

A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.

U. Yasar, K. Laine, J. Widén, 2003, Pharmacology & toxicology.

Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects

L. Bertilsson, J. Widén, G. Tybring, 1997, Clinical pharmacology and therapeutics.

Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19.

T. Tomson, L. Bertilsson, J. Widén, 2003, British journal of clinical pharmacology.

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

L. Bertilsson, K. Laine, S. Härtter, 2001, Clinical pharmacology and therapeutics.

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

L. Bertilsson, M. Dahl, J. Widén, 1991, Acta psychiatrica Scandinavica.

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.

L. Bertilsson, N. Yasui-Furukori, L. Gustafsson, 2003, British journal of clinical pharmacology.

High-performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma.

J. Widén, G. Tybring, J. Nordin, 1998, Journal of chromatography. B, Biomedical sciences and applications.

CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

J. Kennedy, L. Bertilsson, L. Endrenyi, 2007, Pharmacogenetics and genomics.